Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3119.

https://doi.org/10.1182/blood-2024-194561

Published: 2024

Journal Articles

A Phase Ib Clinical Trial Investigating the Safety, Tolerability, and Pharmacokinetics of HX009，a Novel Bsab Dual Targeting PD-1 x CD47，in Patients with EBV + Non-Hodgkin Lymphoma (NHL)

Lin Gui, Keshu Zhou, Ting Liu, Yan Qin, Hongmei Jing, Wenyu Li, Yajun Li, Wenrong Huang, Zhen Wang, Xiuhua Sun, Quan Li, Faming Zhang, Henry Li, Lei Zhang, Peng Sun, Xinbao Gao, Yuankai Shi

Blood (2024) 144 (Supplement 1): 1741.

https://doi.org/10.1182/blood-2024-194771

Published: 2024

Journal Articles

Updated Results from a Phase I Trial of Amulirafusp Alfa (IMM0306) in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma

Yuankai Shi, Jianliang Yang, Yongping Song, Keshu Zhou, Zhiming Li, Mingzhi Zhang, Hongmei Jing, Zhen Wang, Li Yu, Wei Meng, Qiying Lu, Wenzhi Tian

Blood (2024) 144 (Supplement 1): 1632.

https://doi.org/10.1182/blood-2024-200499

Published: 2024

Journal Articles

Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Blood (2024) 144 (Supplement 1): 1635.

https://doi.org/10.1182/blood-2024-194572

Published: 2024

Journal Articles

Health-Related Quality of Life (HRQL) in Cutaneous T-Cell Lymphoma: Psychological Burden and Influencing Factors from Mycosis Fungoides and Sézary Syndrome Patients in China

Tun-Ying Hsu, Huiping Sun, Zhiming Li, Wenrong Huang, Linna Xie, Xiaojing Yan, Haifeng Zhao, Ki Hyon Kim, Yuankai Shi

Blood (2023) 142 (Supplement 1): 7354.

https://doi.org/10.1182/blood-2023-179638

Published: 2023

Journal Articles

Expression Signature and Prognostic Value of BCL2 Translocation for Diffuse Large B-Cell Lymphoma Patients in China

Yan Qin, Tian Qiu, Xinrui Chen, Peng Liu, Jianliang Yang, Xiaohui He, Lin Gui, Shengyu Zhou, Hongxin Jiang, Changgong Zhang, Sheng Yang, Le Tang, Yuankai Shi

Blood (2022) 140 (Supplement 1): 12094–12095.

https://doi.org/10.1182/blood-2022-162307

Published: 2022

Journal Articles

Preliminary Safety and Efficacy Evaluation of IMM0306, a CD47 and CD20 Bispecific Monoclonal Antibody-Trap (mAb-Trap), from an Ongoing Phase I Dose-Escalation Study in Patients with Relapsed or Refractory B-Cell Non- Hodgkin's Lymphoma (R/R B-NHL)

Yuankai Shi, Yongping Song, Mingzhi Zhang, Hongmei Jing, Zhen Wang, Zhiming Li, Junyuan Qi, Fei Li, Wenyu Li, Jianliang Yang, Siman Gao, Huizi Ma, Heming He, Qiying Lu, Wenzhi Tian

Blood (2022) 140 (Supplement 1): 9323–9324.

https://doi.org/10.1182/blood-2022-157862

Published: 2022

Journal Articles

MYD88 L265P Mutation and Other Variants Show Different Molecular Characteristics in Diffuse Large B-Cell Lymphoma Treated with R-CHOP in China

Yan Qin, Tian Qiu, Zucheng Xie, Peng Liu, Jianliang Yang, Xiaohui He, Lin Gui, Shengyu Zhou, Hongxin Jiang, Changgong Zhang, Sheng Yang, Le Tang, Yuankai Shi

Blood (2022) 140 (Supplement 1): 9512–9513.

https://doi.org/10.1182/blood-2022-162907

Published: 2022

Journal Articles

The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Orelabrutinib in Chinese Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Updated Results of a Multicenter, Phase I/IIa Trial

Yuankai Shi, Yan Qin, Aimin Zang, Yufu Li, Yanli Yang, Hui Liu, Sujun Gao, Xinghe Wang, Weijing Zhang, Zhengming Jin, Hui Zhou, Wang Hua-Qing, Min Wei

Blood (2022) 140 (Supplement 1): 9482–9483.

https://doi.org/10.1182/blood-2022-162984

Published: 2022

Journal Articles

Duration of Objective Responses for Patients with Indolent Non-Hodgkin Lymphoma Discontinuing Treatment before Progression: Analysis from the Phase III Chronos-3 Trial Comparing Copanlisib Plus Rituximab with Placebo Plus Rituximab

Matthew J. Matasar, Marcelo Capra, Muhit Özcan, Fangfang Lv, Wei Li, Eduardo Yañez, Katya Sapunarova, Tongyu Lin, Jie Jin, Wojciech Jurczak, Aryan Hamed, Ming-Chung Wang, Lidia Mongay Soler, Anjun Cao, Florian Hiemeyer, Barrett H Childs, Yuankai Shi, Pier Luigi Luigi Zinzani

Blood (2021) 138 (Supplement 1): 3538.

https://doi.org/10.1182/blood-2021-150873

Published: 2021

Journal Articles

Efficacy and Safety of PD-1 Inhibitor Plus Rituximab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Yan Qin, Xiaohui He, Sheng Yang, Peng Liu, Shengyu Zhou, Jianliang Yang, Lin Gui, Qiaofeng Zhong, Fengyi Zhao, Yuankai Shi, Hongmei Jing, Shiyue Zhang, Ruihan Guo, Yuankai Shi

Blood (2021) 138 (Supplement 1): 2485.

https://doi.org/10.1182/blood-2021-152094

Published: 2021

Journal Articles

Efficacy and Safety of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody (SCT400) Combined with CHOP in Patients with Treatment-Naïve Diffuse Large B-Cell Lymphoma: A Multicenter, Randomized, Single-Blind, Parallel Active-Controlled, Phase III Study

Blood (2021) 138 (Supplement 1): 2480.

https://doi.org/10.1182/blood-2021-149861

Published: 2021

Journal Articles

The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Lenalidomide in Chinese Patients with Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma: Results of a Multicenter, Single-Arm, Phase 1b/2 Trial

Yuankai Shi, Yan Qin, Yongping Song, Keshu Zhou, Hui Zhou, Hongmei Jing, Ying Xiang, Zhao Wang, Zhen Wang, Aimin Zang, Ou Bai, Zhenyu Li, Huilai Zhang

Blood (2021) 138 (Supplement 1): 1351.

https://doi.org/10.1182/blood-2021-146440

Published: 2021

Journal Articles

Development and Validation of a Novel Prognostic Nomogram Model and a Web-Based Survival Rate Calculator for Diffuse Large B-Cell Lymphoma in the Rituximab Era

Qiaofeng Zhong, Haizhu Chen, Yan Qin, Xiaohui He, Sheng Yang, Shengyu Zhou, Peng Liu, Yuankai Shi, Hongmei Jing

Blood (2021) 138 (Supplement 1): 1450.

https://doi.org/10.1182/blood-2021-154210

Published: 2021

Journal Articles

Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study

Blood (2019) 134 (Supplement_1): 1568.

https://doi.org/10.1182/blood-2019-123446

Published: 2019

Journal Articles

A Phase 1b/2 Study of Chidamide Combined with CHOP in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL)

Yuankai Shi, MD, Lin Gui, MD, Junning Cao, MD, Huilai Zhang, MD, Jun Zhu, MD PhD, Dongmei Ji, MD PhD, Qian Fan, MD, Yuqin Song, MD PhD, Weina Shen, MM, Guiying Bai, MM, Ming-Zhe Han, MD, Shiyu Jiang

Blood (2019) 134 (Supplement_1): 2840.

https://doi.org/10.1182/blood-2019-128078

Published: 2019

Journal Articles

First China Approved Rituximab Biosimilar HLX01: Pharmacokinetics, Safety and Efficacy Comparison to Reference Rituximab in the Phase 3 Diffuse Large B-Cell Lymphoma Study

Blood (2019) 134 (Supplement_1): 2878.

https://doi.org/10.1182/blood-2019-130603

Published: 2019

Journal Articles

Characterization of Methylation Patterns in Diffuse Large B Cell Lymphoma By Genome-Wide Methylation Analysis

Fengyi Zhao, M.M., Lei Zhang, M.M., Yan Qin, MD, Ming-Zhe Han, MD, Xiaohong Han, MD, Shiyu Jiang, M.M., Yuankai Shi, MD

Blood (2019) 134 (Supplement_1): 1243.

https://doi.org/10.1182/blood-2019-131656

Published: 2019

Journal Articles

A Retrospective Analysis of Outcomes of Diffuse Large B Cell Lymphoma (DLBCL) in the Elder Patients in China

Peng Liu, Ying Han, Jianliang Yang, Xiaohui He, Changgong Zhang, Shengyu Zhou, Yan Qin, Liqiang Zhou, Song Yongwen, Ming-Zhe Han, MD, Yan Sun, Yuankai Shi, MD PhD

Blood (2018) 132 (Supplement 1): 5410.

https://doi.org/10.1182/blood-2018-99-116641

Published: 2018

Journal Articles

Plinabulin, a Novel Small Molecule in Development for Chemotherapy-Induced-Neutropenia (CIN) Prevention, Mobilizes CD34+ Cells through a Mechanism of Action (MoA) Different from G-CSF and from CXCR4 Inhibition

Douglas W. Blayney, MD, Ene Ette, PhD, Stephan Ogenstad, PhD, Yuankai Shi, MD PhD, Lihua Du, Kenneth Lloyd, PhD, Lan Huang, PhD, Ramon Mohanlal, PhD MD

Blood (2018) 132 (Supplement 1): 2068.

https://doi.org/10.1182/blood-2018-99-113569

Published: 2018

NARROW

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

A Phase Ib Clinical Trial Investigating the Safety, Tolerability, and Pharmacokinetics of HX009，a Novel Bsab Dual Targeting PD-1 x CD47，in Patients with EBV + Non-Hodgkin Lymphoma (NHL)

Updated Results from a Phase I Trial of Amulirafusp Alfa (IMM0306) in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma

Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Health-Related Quality of Life (HRQL) in Cutaneous T-Cell Lymphoma: Psychological Burden and Influencing Factors from Mycosis Fungoides and Sézary Syndrome Patients in China

Expression Signature and Prognostic Value of BCL2 Translocation for Diffuse Large B-Cell Lymphoma Patients in China

Preliminary Safety and Efficacy Evaluation of IMM0306, a CD47 and CD20 Bispecific Monoclonal Antibody-Trap (mAb-Trap), from an Ongoing Phase I Dose-Escalation Study in Patients with Relapsed or Refractory B-Cell Non- Hodgkin's Lymphoma (R/R B-NHL)

MYD88 L265P Mutation and Other Variants Show Different Molecular Characteristics in Diffuse Large B-Cell Lymphoma Treated with R-CHOP in China

The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Orelabrutinib in Chinese Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Updated Results of a Multicenter, Phase I/IIa Trial

Duration of Objective Responses for Patients with Indolent Non-Hodgkin Lymphoma Discontinuing Treatment before Progression: Analysis from the Phase III Chronos-3 Trial Comparing Copanlisib Plus Rituximab with Placebo Plus Rituximab

Efficacy and Safety of PD-1 Inhibitor Plus Rituximab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Efficacy and Safety of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody (SCT400) Combined with CHOP in Patients with Treatment-Naïve Diffuse Large B-Cell Lymphoma: A Multicenter, Randomized, Single-Blind, Parallel Active-Controlled, Phase III Study

The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Lenalidomide in Chinese Patients with Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma: Results of a Multicenter, Single-Arm, Phase 1b/2 Trial

Development and Validation of a Novel Prognostic Nomogram Model and a Web-Based Survival Rate Calculator for Diffuse Large B-Cell Lymphoma in the Rituximab Era

Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study

A Phase 1b/2 Study of Chidamide Combined with CHOP in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL)

First China Approved Rituximab Biosimilar HLX01: Pharmacokinetics, Safety and Efficacy Comparison to Reference Rituximab in the Phase 3 Diffuse Large B-Cell Lymphoma Study

Characterization of Methylation Patterns in Diffuse Large B Cell Lymphoma By Genome-Wide Methylation Analysis

A Retrospective Analysis of Outcomes of Diffuse Large B Cell Lymphoma (DLBCL) in the Elder Patients in China

Plinabulin, a Novel Small Molecule in Development for Chemotherapy-Induced-Neutropenia (CIN) Prevention, Mobilizes CD34+ Cells through a Mechanism of Action (MoA) Different from G-CSF and from CXCR4 Inhibition

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only